<DOC>
	<DOCNO>NCT01129258</DOCNO>
	<brief_summary>The purpose study characterize safety , tolerability , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) PF-04991532 follow multiple ( 14 day ) escalate oral dos patient wtih type 2 diabetes .</brief_summary>
	<brief_title>Multiple Dose Study PF-04991532 Patients With Type 2 Diabetes</brief_title>
	<detailed_description>Safety/Tolerability , PK , PD</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Glucose Metabolism Disorders</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<criteria>Patients type 2 diabetes mellitus take metformin . Treatment stable , defined change treatment , include dose , past 2 month . Subjects treat sulfonylurea ( SU ) dipeptidyl peptidase4 inhibitor ( DPP4i ) combination metformin may eligible washed SU DPP4i metformin minimum 4 week dose . Subjects switch SU metformin DPP4i metformin metformin still need meet fast glucose requirement Day 2 define protocol . Body Mass Index ( BMI ) 18.5 45.0 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . Fasting Cpeptide &gt; 0.8 ng/mL . HbA1c &gt; /=7 % &gt; /=10 % . If patient require washed SU DPP4i , HbA1c limit &gt; /=6.5 % &lt; /=9 % . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease . Subjects chronic condition T2DM ( example , hypercholesterolemia hypertension ) control either diet stable ( last 2 month ) dose medication may include well . Evidence history diabetic complication significant endorgan damage . Any condition possibly affect drug absorption ( eg , gastrectomy ) . History stroke , transient ischemic attack , myocardial infarction within past 6 month . History coronary artery bypass graft stent implantation . Clinically significant peripheral vascular disease . Any history clinical evidence congestive heart failure , NYHA Classes IIIV . Current history angina/unstable angina . ECG finding suggestive asymptomatic myocardial ischemia QTc &gt; 470 msec screening . One selfreported episode hypoglycemia within last 3 month , two selfreported episode hypoglycemia within last 6 month . Screening Day 2 fasting ( &gt; /=8 hour ) glucose , &lt; /=90 &gt; /=270 mg/dL , confirm single repeat deem necessary . A positive urine drug screen . Use tobacco nicotinecontaining product excess equivalent 10 cigarette per day . History regular alcohol consumption exceed 7 drinks/week female 14 drinks/week male ( 1 drink = 5 ounce ( 150 mL ) wine 12 ounce ( 360 mL ) beer 1.5 ounce ( 45 mL ) hard liquor ) within 6 month screen . Certain concomitant medication exclude , define protocol . Screening supine blood pressure &gt; /=160 mm Hg ( systolic ) &gt; /=100 mm Hg ( diastolic ) . Certain laboratory value ( example , triglyceride liver function test result ) . Pregnant nursing female ; female childbearing potential .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>phase 1</keyword>
	<keyword>safety tolerability</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>PK</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>PD</keyword>
	<keyword>type 2 diabetes mellitus</keyword>
</DOC>